Study On The Clinicopathological Features And Prognosis Of Non - Small Cell Lung Cancer Based On EGFR, KRAS And ALK

[Objectiv] To analyze the clinical, pathological, and prognostic features of non-small cell lung cancer based on the mutation status of EGFR, KRAS, ALK and EGFR mutation subtypes[Methods] The medical records of 1975 patients diagnosed with NSCLC at the cancer hospital of Chinese Academy of Medical Sciences from July 2002 to February 2013 were retrospectively reviewed. The medical records included the demographics, smoking status, family history, clinical stage, tumor stage, tumor size, histological type, degree of differentiation and survival data. The analyis was based on the different molecular pathological type.[Results] Patients with EGFR-positive mutations, especially EGFR classic mutations, hadgood biological tumor behaviors and good prognosis, with a MST of 61.6 months; KRAS-positive mutation NSCLC hada high incidence in male smokers over 50 years old, and the prognosis was relative poor, with a MST of 26.0 months; ALK-positive mutation favored in young non-smoking women, tumors developed fast in the beginning and tended to metastasize, with a MST of 32.3 months. Gefitinib, erlotinib and icotinib had similar clinical efficacy, did not improve overall survival compared with chemotherapy in EGFR-positive NSCLC patients.[Conclusion] There are great differences in clinical, pathological and prognostic features in EGFR, KRAS and ALK positive subgroup. Detection mutation status of EGFR, KRAS, and ALK in NSCLC is important in judging the clinical and pathological characteristics and prognosis.